Clinical Trial Update: Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) [Phase 3]

View source ↗

Summary

A Phase 3 study (EOS) evaluating the effect of roflumilast on lung function in COPD patients who are treated with salmeterol has completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)
• Serevent (salmeterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2011-05-19